Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion
暂无分享,去创建一个
R. Shannon | D. Elahi | S. Mankad | G. Sokos | L. Nikolaidis | G. Miske | Ankur G Shah
[1] N. Reichek,et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[2] H. Taegtmeyer,et al. Metabolic support for the postischaemic heart , 1995, The Lancet.
[3] J. Holst,et al. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7–36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships , 1995, Diabetologia.
[4] J. Habener,et al. The glucagon-like peptides. , 1999, Endocrine reviews.
[5] H. Taegtmeyer,et al. Glucose-insulin-potassium in acute myocardial infarction: the time has come for a large, prospective trial. , 1997, Circulation.
[6] K. Kent,et al. Metabolic support during coronary reperfusion. , 1987, American heart journal.
[7] L. Piegas,et al. Metabolic Modulation of Acute Myocardial Infarction The ECLA Glucose-Insulin-Potassium Pilot Trial , 1998 .
[8] C. Apstein. Glucose-insulin-potassium for acute myocardial infarction: remarkable results from a new prospective, randomized trial. , 1998, Circulation.
[9] D. Yellon,et al. Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. , 2003, Journal of the American College of Cardiology.
[10] L. Opie. Proof that glucose-insulin-potassium provides metabolic protection of ischaemic myocardium? , 1999, The Lancet.
[11] Felix Zijlstra,et al. Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. , 2003, Journal of the American College of Cardiology.
[12] G. Billman,et al. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. , 2003, Circulation.
[13] S. Kahn,et al. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. , 1994, The Journal of clinical investigation.
[14] J Herlitz,et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. , 1995, Journal of the American College of Cardiology.
[15] K. Beatt,et al. Glucose-insulin-potassium in acute myocardial infarction , 1999, The Lancet.
[16] L. Rydén,et al. Glucagon-like peptide-1 (7–36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium , 2003, Peptides.